Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone
Meets Primary Endpoint In Phase III MARIGOLD Study
Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.
